Orobol

Research use only, not for human use.

Orobol is an inhibitor of tyrosine-specific protein kinase and phosphatidylinositol turnover. Orobol inhibits PI3K isoforms with IC50s of 3.46-5.27 μM for PI3K α/β/γ/K/δ. Orobol exhibits anti-skin-aging and anti-obesity effects.

Orobol is an inhibitor of tyrosine-specific protein kinase and phosphatidylinositol turnover. Orobol inhibits PI3K isoforms with IC50s of 3.46-5.27 μM for PI3K α/β/γ/K/δ. Orobol exhibits anti-skin-aging and anti-obesity effects.(In Vitro):Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK with IC50s of 1.24-4.45 μM. Orobol (5-20 μM) effectively suppresses MDI (isobutylmethylxanthine, dexamethasone, and insulin (MDI))-induced phosphorylation of 4E-BP1. Orobol binds to CK1ε in an ATP-competitive manner.(In Vivo):In C57BL/6J mice, Orobol (10 mg/kg; intragastrically) attenuates high-fat diet-induced weight gain (17.3%) and lipid accumulation without affecting food intake.

Orobol binds to CK1ε in an ATP-competitive manner and exerts anti-obesity effects by targeting casein kinase 1 epsilon.Orobol (5-20 μM) effectively suppresses MDI (isobutylmethylxanthine, dexamethasone and insulin (MDI))-induced phosphorylation of 4E-BP1.

Orobol attenuates high fat diet-induced weight gain and lipid accumulation without affecting food intake in C57BL/6J mice. Animal Model:HFD-induced obesity in C57BL/6J mice Dosage:10?mg/kg Administration: Intragastrically; daily for 23 weeks Result:Significantly reduced body weight by 17.3% compared to the HFD group.

3'-Hydroxygenistein | 3’,4’,5,7-tetrahydroxy-isoflavon

Angiogenesis

Bcl-2

BCL

——

——

480-23-9

286.239

C15H10O6

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (174.68 mM)

Oc1cc(O)c2c(c1)occ(-c1ccc(O)c(O)c1)c2=O

——

(-20℃)

With Ice Pack

≥ 2 years